Stanley L Liauw

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4646236/publications.pdf

Version: 2024-02-01

132 papers	4,866 citations	172457 29 h-index	95266 68 g-index
133 all docs	133 docs citations	133 times ranked	5186 citing authors

#	Article	IF	Citations
1	Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy. Journal of Clinical Oncology, 2007, 25, 2035-2041.	1.6	836
2	Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2004, 291, 1325.	7.4	588
3	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. Journal of Clinical Oncology, 2016, 34, 3648-3654.	1.6	296
4	Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter Experience. Journal of Clinical Oncology, 2007, 25, 4581-4586.	1.6	252
5	New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. Science Translational Medicine, 2013, 5, 173sr2.	12.4	197
6	Postradiotherapy Neck Dissection for Lymph Nodeâ€“Positive Head and Neck Cancer: The Use of Computed Tomography to Manage the Neck. Journal of Clinical Oncology, 2006, 24, 1421-1427.	1.6	160
7	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. Journal of Urology, 2019, 202, 272-281.	0.4	157
8	Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. Journal of Clinical Oncology, 2010, 28, 2653-2659.	1.6	146
9	Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. International Journal of Radiation Oncology Biology Physics, 2006, 66, 669-673.	0.8	122
10	A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology, 2008, 72, 1298-1302.	1.0	103
11	Aspirin Use and the Risk of Prostate Cancer Mortality in Men Treated With Prostatectomy or Radiotherapy. Journal of Clinical Oncology, 2012, 30, 3540-3544.	1.6	98
12	Late Toxicity After Intensity-Modulated Radiation Therapy for Localized Prostate Cancer: An Exploration of Doseâ€“Volume Histogram Parameters to Limit Genitourinary and Gastrointestinal Toxicity. International Journal of Radiation Oncology Biology Physics, 2012, 82, 235-241.	0.8	97
13	Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 589-595.	1.3	87
14	Evaluation of the Prostate Bed for Local Recurrence After Radical Prostatectomy Using Endorectal Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2013, 85, 378-384.	0.8	77
15	External Beam Radiotherapy for Prostate Cancer Patients on Anticoagulation Therapy: How Significant is the Bleeding Toxicity?. International Journal of Radiation Oncology Biology Physics, 2010, 76, 755-760.	0.8	67
16	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncology, 2018, 4, e175230.	7.1	65
17	Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease. Cancer, 2004, 100, 920-928.	4.1	62
18	Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology, 2003, 61, 1204-1210.	1.0	55

#	Article	IF	Citations
19	Lymph nodeâ€positive head and neck cancer treated with definitive radiotherapy. Cancer, 2008, 112, 1076-1082.	4.1	55
20	The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer, 2010, 116, 1820-1826.	4.1	50
21	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomyâ€"A Multi-Institutional Observational Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1046-1053.	0.8	47
22	Radiotherapy after subtotally resected or recurrent ganglioglioma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 244-247.	0.8	46
23	External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men With High International Prostate Symptom Scores (IPSS). International Journal of Radiation Oncology Biology Physics, 2011, 80, 1080-1086.	0.8	42
24	Age and Grade Trends in Prostate Cancer (1974â€“2003). American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 375-378.	1.3	41
25	External Beam Radiation Therapy After Transurethral Resection of the Prostate: A Report on Acute and Late Genitourinary Toxicity. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1060-1065.	0.8	37
26	The role of radiotherapy in locally advanced pancreatic carcinoma. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 437-447.	17.8	36
27	Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1031-1039.	0.8	33
28	ACR Appropriateness Criteria Renal Cell Carcinoma Staging. Journal of the American College of Radiology, 2016, 13, 518-525.	1.8	32
29	ACR Appropriateness Criteria Â® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Advances in Radiation Oncology, 2017, 2, 62-84.	1.2	30
30	Toxicity After External Beam Radiotherapy for Prostate Cancer: An Analysis of Late Morbidity in Men With Diabetes Mellitus. Urology, 2013, 81, 1196-1201.	1.0	29
31	Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: Salvage in the dissected or undissected neck. Head and Neck, 2007, 29, 715-719.	2.0	28
32	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. European Urology, 2018, 74, 99-106.	1.9	28
33	Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: A report of total setup error, required PTV expansion, and dosimetric implications. Radiotherapy and Oncology, 2012, 103, 270-274.	0.6	27
34	Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. International Journal of Radiation Oncology Biology Physics, 2017, 97, 306-312.	0.8	27
35	The Effect of Intravenous Contrast on Intensity-Modulated Radiation Therapy Dose Calculations for Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 456-459.	1.3	26
36	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy, 2017, 16, 266-276.	0.5	26

#	Article	IF	Citations
37	The role of the radiation oncologist in goals-of-care discussions.. Journal of Clinical Oncology, 2015, 33, 42-42.	1.6	26
38	Biochemical Control and Toxicity after Intensity-Modulated Radiation Therapy for Prostate Cancer. Technology in Cancer Research and Treatment, 2009, 8, 201-206.	1.9	25
39	Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. Journal of the National Cancer Institute, 2020, 112, 847-854.	6.3	23
40	Prostate Cancer Modality Time Trend Analyses From 1973 to 2004. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 168-172.	1.3	23
41	Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence. Annals of Surgical Oncology, 2012, 19, 2471-2476.	1.5	22
42	Clinical Outcomes for Gastric Cancer following Adjuvant Chemoradiation Utilizing Intensity Modulated versus Three-Dimensional Conformal Radiotherapy. PLoS ONE, 2014, 9, e82642.	2.5	22
43	Radiation oncology residency selection: A postgraduate evaluation of factor importance and survey of variables associated with job securement. Practical Radiation Oncology, 2017, 7, 425-432.	2.1	21
44	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Advances in Radiation Oncology, 2017, 2, 437-454.	1.2	21
45	Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. Cancer, 2013, 119, 2807-2814.	4.1	20
46	Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity modulated radiation therapy. Practical Radiation Oncology, 2013, 3, e1-e9.	2.1	19
47	Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. Practical Radiation Oncology, 2013, 3, 138-144.	2.1	19
48	Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. International Journal of Radiation Oncology Biology Physics, 2018, 102, 304-313.	0.8	19
49	Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensityâ€modulated radiation therapy. Cancer Medicine, 2014, 3, 954-961.	2.8	18
50	Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. European Urology, 2019, 76, 686-692.	1.9	18
51	Doseâ€escalated radiation therapy for intermediateâ€risk prostate cancer. Cancer, 2009, 115, 1784-1790.	4.1	17
52	Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 416.e15-416.e21.	1.6	17
53	Late rectal toxicity after prostate brachytherapy: Influence of supplemental external beam radiation on doseâ€“volume histogram analysis. Brachytherapy, 2010, 9, 131-136.	0.5	16
54	Considering the role of radiation therapy for gastrointestinal stromal tumor. OncoTargets and Therapy, 2014, 7, 713.	2.0	16

#	Article	IF	Citations
55	Radiation dose â‰¥54 Gy and CA 19â€“9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiation Oncology, 2012, 7, 156.	2.7	15
56	A Surveillance, Epidemiology, and End Results Registry Analysis of Prostate Cancer Modality Time Trends by Age. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 619-623.	1.3	14
57	Dose-Escalated Radiotherapy for High-Risk Prostate Cancer: Outcomes in Modern Era With Short-Term Androgen Deprivation Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 125-130.	0.8	14
58	Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments. Journal of Applied Clinical Medical Physics, 2020, 21, 184-191.	1.9	14
59	High-Dose Radiotherapy With or Without Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer: Cancer Control and Toxicity Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1473-1479.	0.8	13
60	PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 600.e1-600.e8.	1.6	13
61	Salvage Radiotherapy After Postprostatectomy Biochemical Failure: Does Pretreatment Radioimmunoscintigraphy Help Select Patients with Locally Confined Disease?. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1316-1321.	0.8	12
62	Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes. PLoS ONE, 2015, 10, e0141639.	2.5	12
63	Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 38-46.	1.7	11
64	Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer. Scientific World Journal, The, 2010, 10, 1854-1869.	2.1	10
65	Prostate-Specific Antigen Halving Time While on Neoadjuvant Androgen Deprivation Therapy Is Associated With Biochemical Control in Men Treated With Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1022-1028.	0.8	10
66	Image-guided radiation therapy for prostate cancer: A computed tomographyâ€“based assessment of fiducial marker migration between placement and 7 days. Practical Radiation Oncology, 2015, 5, 241-247.	2.1	10
67	A Prostate Fossa Contouring Instructional Module: Implementation and Evaluation. Journal of the American College of Radiology, 2016, 13, 835-841.e1.	1.8	10
68	Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 612-620.	1.3	10
69	ACR Appropriateness CriteriaÂ® Locally Advanced, High-Risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 1-10.	1.3	10
70	Prolongation of Total Treatment Time Because of Infrequently Missed Days of Treatment Is Not Associated With Inferior Biochemical Outcome After Dose-Escalated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 751-757.	0.8	9
71	Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2016, 6, e179-e185.	2.1	9
72	Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 471.e11-471.e18.	1.6	9

#	Article	IF	Citations
73	18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Practical Radiation Oncology, 2020, 10, 354-362.	2.1	9
74	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	9
75	The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients. Clinical Medicine and Research, 2007, 5, 123-131.	0.8	8
76	Management of Low-Stage Testicular Seminoma. Urologic Clinics of North America, 2015, 42, 287-298.	1.8	8
77	The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2015, 5, e223-e228.	2.1	8
78	External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 740-746.	0.8	7
79	Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e12-e18.	1.9	7
80	A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. Journal of Gastrointestinal Oncology, 2020, 11, 1399-1407.	1.4	7
81	Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer?. Academic Radiology, 2022, 29, 977-985.	2.5	7
82	Definitive radiotherapy for head-and-neck cancer with radiographically positive retropharyngeal nodes: Incomplete radiographic response does not necessarily indicate failure. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1017-1021.	0.8	6
83	Validation of Normal Tissue Complication Probability Predictions in Individual Patient: Late Rectal Toxicity. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1103-1109.	0.8	6
84	A Pancreatic Predicament. International Journal of Radiation Oncology Biology Physics, 2017, 99, 296-297.	0.8	6
85	Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines. Advances in Radiation Oncology, 2018, 3, 339-345.	1.2	6
86	Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and SÃ©zary syndrome. British Journal of Haematology, 2019, 186, 377-379.	2.5	6
87	Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression. Cancer Medicine, 2020, 9, 4667-4675.	2.8	6
88	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
89	Comfort Level of US Radiation Oncology Graduates: Assessment of Transition to Independent Clinical Practice. Journal of Cancer Education, 2021, 36, 278-283.	1.3	6
90	Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. PLoS ONE, 2018, 13, e0194234.	2.5	6

#	Article	IF	Citations
91	Herpes zoster and radiation therapy: What radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster. Practical Radiation Oncology, 2014, 4, 58-64.	2.1	5
92	High-risk Prostate Cancer Treated With Dose-escalated RT. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 348-352.	1.3	5
93	The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update. Current Urology Reports, 2017, 18, 50.	2.2	5
94	Oncology Scanâ€"Novel Treatment Strategies for Gastrointestinal Cancers. International Journal of Radiation Oncology Biology Physics, 2014, 89, 699-703.	0.8	4
95	Goals of care discussions: perceptions of radiation and medical oncologists. Supportive Care in Cancer, 2021, 29, 7279-7288.	2.2	4
96	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Annals of Surgical Oncology, 2022, 29, 4583-4592.	1.5	4
97	Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.. Journal of Clinical Oncology, 2022, 40, 5012-5012.	1.6	4
98	Whole-abdomen radiotherapy for non-Hodgkinâ€™s lymphoma using twice-daily fractionation. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1440-1445.	0.8	3
99	The Use of Capecitabine in the Combined-Modality Therapy for Rectal Cancer. Clinical Colorectal Cancer, 2008, 7, 99-104.	2.3	3
100	Effects of aspirin on cancer initiation and progression. Expert Review of Anticancer Therapy, 2013, 13, 115-117.	2.4	3
101	Randomized Trials and New Directions inÂGastrointestinal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 459-464.	0.8	3
102	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	2.6	3
103	Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 382-390.	1.3	3
104	A prospective clinical and transcriptomic feasibility study of oralâ€only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer, 2021, 127, 2631-2640.	4.1	3
105	Chemoradiation for Anal Cancer: Clinical Outcomes and Strategies to Optimize the Therapeutic Ratio According to HPV Status. Seminars in Radiation Oncology, 2021, 31, 349-360.	2.2	3
106	Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. OncoTargets and Therapy, 2013, 6, 1097.	2.0	2
107	Combined-modality Therapy for Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 122-125.	1.3	2
108	Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. Journal of Surgical Education, 2018, 75, 434-441.	2.5	2

#	Article	IF	Citations
109	Circulating tumor-tissue modified HPV DNA analysis for molecular disease monitoring after chemoradiation for anal squamous cell carcinoma: a case report. Journal of Gastrointestinal Oncology, 2021, 12, 3155-3162.	1.4	2
110	Key New Studies in Gastric and Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 475-481.	0.8	1
111	Gastrointestinal Cancersâ€"Changing the Standard forÂRectal Cancer and Establishing a New Standard forÂLiverÂTumors. International Journal of Radiation Oncology Biology Physics, 2016, 95, 930-936.	0.8	1
112	Managing Cancer Relapse After Radical Prostatectomy. Urologic Clinics of North America, 2017, 44, 597-609.	1.8	1
113	The perils of using registry data to compare the survival and cost of radical cystectomy and trimodality therapy in bladder cancer. Translational Andrology and Urology, 2019, 8, S533-S537.	1.4	1
114	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access Journal of Urology, 2011, 3, 95-104.	0.3	1
115	Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. Journal of Urology, 2022, 207, 1236-1245.	0.4	1
116	Reply to H.W. Daniell and to L. Azoulay and S. Suissa. Journal of Clinical Oncology, 2010, 28, e645-e646.	1.6	0
117	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Research and Reports in Urology, 0, Volume 3, 95-104.	1.0	0
118	Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability. Journal of Gastrointestinal Cancer, 2012, 43, 202-207.	1.3	0
119	In Reply to Zaghloul. International Journal of Radiation Oncology Biology Physics, 2016, 95, 855.	0.8	0
120	Pancreatic, Rectal, and Liver Cancers: Out With the Old, In With the New. International Journal of Radiation Oncology Biology Physics, 2017, 97, 643-650.	0.8	0
121	Gastrointestinal Cancers: Timing Is Everything. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1051-1058.	0.8	0
122	Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies. JNCI Cancer Spectrum, 2020, 4, pkaa081.	2.9	0
123	Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.. Journal of Clinical Oncology, 2021, 39, 195-195.	1.6	0
124	High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure. European Urology, 2021, 80, 147-148.	1.9	0
125	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, 9-9.	1.6	0
126	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. Journal of Clinical Oncology, 2017, 2017, 9-9.	1.6	0

#	Article	IF	Citations
127	External validation and optimization of international consensus clinical target volumes for adjuvant radiation in bladder cancer.. Journal of Clinical Oncology, 2017, 35, 336-336.	1.6	0
128	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.. Journal of Clinical Oncology, 2018, 36, 24-24.	1.6	0
129	Regional Influence of Radiation Oncology Residency Training on Job Securement over Two Time Periods. Cureus, 2019, 11, e4495.	0.5	0
130	A prospective study evaluating oral-only hormonal therapy with radiation for intermediate or high-risk prostate cancer in men age â‰¥ 70 years or with moderate comorbidity.. Journal of Clinical Oncology, 2020, 38, 303-303.	1.6	0
131	Reflections on Anthony Zietman From Gastrointestinal Cancer and Physics Editors. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1114-1117.	0.8	0
132	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000000244302.	0.4	0